Release Time：2024-10-18 16:10:52
Author：小编
Views：
From September 19 to 21, the 16th China Bio-Industry Conference was grandly held in Guangzhou's Bio Island.
Numerous enterprises and institutions in the bio-industry have gathered together to celebrate this grand occasion. The China Bio-Industry Conference is the most influential large-scale comprehensive event in China's life sciences, biotechnology, and bio-industry sectors.
The theme of this conference is "Creating a New Industry for Bio-Manufacturing and Opening Up New Tracks in Life Sciences," attracting numerous leading enterprises in the bio-industry to participate in the exhibition.
EVERON HEALTHCARE was also fortunate to participate in this event, showcasing its core achievement - recombinant humanized collagen - as a highlight of the conference.
EVERON HEALTHCARE has been deeply involved in the research and development of innovative products within the biotechnology field. Our products, distinguished by their unique "Ultimate Triple Helix" advantage, offer people a completely new experience and delightful surprises.
EVERON HEALTHCARE 's research and development of recombinant humanized collagen, featuring a remarkable 196 Fahrenheit high-temperature reversibility, has successfully tackled a significant challenge in industrial applications.
At the conference venue, the EVERON HEALTHCARE booth was bustling with activity. Experts and scholars were full of praise for its technological innovations, while numerous merchants showed a keen interest in the products, engaging in deep discussions with EVERON HEALTHCARE staff to explore potential collaboration opportunities.
At this exhibition, EVERON HEALTHCARE not only showcased its formidable capabilities but also embarked on a new chapter in the extensive application of recombinant humanized collagen within the vast arena of the bioindustry. This development is poised to inject significant momentum into the future growth of the bioindustry.
Hengyi Biological official accountCopyright ©2007-2024 All Rights Reserved Dongguan Hengyi Biotechnology Co., Ltd 粤ICP备2024274226号
